Wenzel Spine Announces Leadership Changes

Wenzel Spine, Inc., a medical technology company focused on providing minimally invasive surgical and diagnostic solutions for the treatment of spinal disorders, today announced that its Board of Directors has appointed Dr. Warren Neely as Chairman of the Board and William E. Wilson, President and Chief Executive Officer.

On March 7th, 2022, the unexpected passing of Wenzel Spine’s former President and CEO, Chad G. Neely, left many in the Wenzel Spine community stunned. Dr. Philip Sanger, Managing Partner of TEXO Ventures, said, “We are all going to miss Chad and the presence that he had with company employees, partners, and investors. We are fortunate that Dr. Warren Neely has graciously accepted the position of Chairman of the Board for Wenzel Spine. Dr. Neely is an experienced neurosurgeon who was an early proponent of the VariLift® System and has been actively involved in Wenzel Spine’s development.”

In addition, Wenzel Spine’s Board has appointed William E. (Bill) Wilson as President and Chief Executive Officer of Wenzel Spine. As a founding member of Wenzel Spine, Bill has built his career as an operations management and organizational leader, responsible for the development of the operations, finance, client relations, marketing, strategic partnerships, and medical education teams at Wenzel Spine. Bill’s experience and expertise have enabled him to expertly manage the continuously expanding team and product portfolio. Bill is focused on ensuring that the company’s growth is always centered around Wenzel’s surgeon partners and bringing value to their patients. With Bill’s background in software design and development, Bill can bring a unique perspective to the newest diagnostic solution offering at Wenzel Spine.

TEXO Ventures, Redmont Capital and iNetworks are excited about Bill Wilson assuming his new role as CEO of Wenzel Spine. Bill has been the COO of Wenzel Spine for 13 years and has the experience, knowledge, and vision to take the company forward in a successful manner. “I join our Board of Directors to proudly endorse Bill Wilson as our new CEO, he is the right leader for Wenzel Spine,” said Dr. Warren Neely, Wenzel Spine’s Chairman of the Board. “We are fortunate that Bill and Chad have worked so closely together over the past 13 years. Wenzel Spine is a very strong company, and we plan to continue moving forward in the direction that Chad, Bill, and our Board have always envisioned.”

Commenting on his appointment as CEO, Bill Wilson remarked, “This is a bittersweet transition for us all at Wenzel Spine. I am honored by the request and support of the Board to lead Wenzel Spine into its next chapter of growth and development. Wenzel has some truly innovative products and diagnostic automation technologies in the pipeline to help surgeons and their patients. For Wenzel Spine, our amazing team, and our partners, I am excited about our future.”

Bill holds Bachelor’s degree in Physiology and Computer Science and a Master’s in Computer Science from Michigan State University and his MBA from the University of Texas at Austin.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”